ISSN 2306-5559 (print)
ISSN 2410-938X (online)
ISSN 2410-938X (online)
autors declare no conflict of interest
1. Walldius, G., & Jungner, I. (2004). Apolipoprotein B and apolipoprotein A‐I: Risk indicators of coronary heart disease and targets for lipid‐modifying therapy. Journal of Internal Medicine, 255, 229–238. https://doi.org/10.1046/j.1365-2796.2003.01276.x2. Zhu, Y., Verma, S., Fung, M., McQueen, M., Anderson, T., & Lonn, E. (2017). Association of apolipoproteins B and A-1 with markers of vascular health or cardiovascular events. The Canadian Journal of Cardiology, 33(10), 1305–1311. https://doi.org/10.1016/j.cjca.2017.08.0043. Boekholdt, S., Arsenault, B., Mora, S., Pedersen, T., Larosa, J., Nestel, P., Simes, R., Durrington, P., Hitman, G., Welch, K., Demicco, D., Zwinderman, A., Clearfield, M., Downs, J., Tonkin, A., Colhoun, H., Gotto, A., Ridker, P., & Kastelein, J. (2012). Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: A meta-analysis. JAMA, 307(12), 1302–1309. https://doi.org/10.1001/jama.2012.3664. Tamang, H., Timilsina, U., Singh, K., Shrestha, S., Raman, R., Panta, P., Karna, P., Khadka, L., & Dahal, C. (2014). Apo B/Apo A-I ratio is statistically a better predictor of cardiovascular disease (CVD) than conventional lipid profile: A study from Kathmandu Valley, Nepal. Journal of Clinical and Diagnostic Research: JCDR, 8(2), 34–36. https://doi.org/10.7860/JCDR/2014/7588.40005. Walldius, G., & Jungner, I. (2007). Is there a better marker of cardiovascular risk than LDL cholesterol? Apolipoproteins B and A-I—New risk factors and targets for therapy. Nutrition, Metabolism, and Cardiovascular Diseases: NMCD, 17(8), 565–571. https://doi.org/10.1016/J.NUMECD.2007.02.0106. Carr, S., Hooper, A., Sullivan, D., & Burnett, J. (2019). Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment. Pathology, 51(2), 148–154. https://doi.org/10.1016/j.pathol.2018.11.0067. Young Gil, C., Wook Jin, Y. K., Won Gil, C., Hong Joo, K., Woo Kyu, J., & Byung Ik, K. (2017). Apolipoprotein B/A1 ratio is independently associated with non-alcoholic fatty liver disease in nondiabetic subjects.8. Younossi, Z. M., et al. (2016). Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 64(1), 73–84.9. Eckel, R. H., Grundy, S. M., & Zimmet, P. Z. (2005). The metabolic syndrome. The Lancet, 365(9468), 1415–1428.10. Siddiqui, M. S., et al. (2015). Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile. Clinical Gastroenterology and Hepatology, 13(5), 1000–1008.e3.11. Griffin, B. A. (1999). Lipoprotein atherogenicity: An overview of current mechanisms. Proceedings of the Nutrition Society, 58(1), 163–169.12. Charlton, M., et al. (2002). Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology, 35(4), 898–904.13. Shang, Y., et al. (2022). Risk of cardiovascular disease and loss in life expectancy in NAFLD. Hepatology, 76(5), 1495–1505.14. McPherson, S., et al. (2015). Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management. Journal of Hepatology, 62(5), 1148–1155.15. Younossi, Z. M., et al. (2016). Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 64(1), 73–84.16. Hassen, G., et al. (2022). Nonalcoholic fatty liver disease: An emerging modern-day risk factor for cardiovascular disease. Cureus, 14.17. Taylor, R. S., et al. (2020). Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis. Gastroenterology, 158(6), 1611–1625.e12.18. Younossi, Z., et al. (2019). Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology, 69(6), 2672–2682.19. Younossi, Z., et al. (2019). Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology, 69(6), 2672–2682.20. Liu, Y., et al. (2019). Nonalcoholic fatty liver disease and mortality from all causes, cardiovascular disease, and cancer: A meta-analysis. Scientific Reports, 9(1), 11124.21. Sanyal, A. J., et al. (2021). Prospective study of outcomes in adults with nonalcoholic fatty liver disease. New England Journal of Medicine, 385(17), 1559–1569.22. Katsiki, N., Mikhailidis, D. P., & Mantzoros, C. S. (2016). Non-alcoholic fatty liver disease and dyslipidemia: An update. Metabolism, 65(8), 1109–1123.23. Siddiqui, M. S., et al. (2015). Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile. Clinical Gastroenterology and Hepatology, 13(5), 1000–1008.e3.24. Hwang, H. W., et al. (2020). Correlation between the small dense LDL level and nonalcoholic fatty liver disease: Possibility of a new biomarker. Medicine, 99(28).